Measurement of the drug sensitivity of single prostate cancer cells

Fikri Abali; Narges Baghi; Lisanne Mout; Joska J. Broekmaat; Arjan G.J. Tibbe; Leon W.M.M. Terstappen

doi:10.3390/cancers13236083

Measurement of the drug sensitivity of single prostate cancer cells

Fikri Abali^*, Narges Baghi, Lisanne Mout, Joska J. Broekmaat, Arjan G.J. Tibbe, Leon W.M.M. Terstappen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

131 Downloads (Pure)

Abstract

The treatment of cancer faces a serious challenge as cancer cells within patients are heterogeneous and frequently resistant to therapeutic drugs. Here, we introduce a technology enabling the assessment of single cancer cells exposed to different drugs. PCa cells were individually sorted in self-seeding microwells, cultured for 24 h, and then exposed to several drugs to induce (R1881) or inhibit (Enzalutamide/Abiraterone) the secretion of a protein (PSA). Cell viability and PSA secretion of each individual prostate cell were monitored over a 3-day period. The PSA protein secreted by each cell was captured on a PVDF membrane through a pore in the bottom of each well. The basal PSA secretion was found to be 6.1 ± 4.5 and 3.7 ± 1.9 pg/cell/day for LNCaP and VCaP, respectively. After exposure to R1881, the PSA secretion increased by ~90% on average and was not altered for ~10% of the cells. PSA production decreased in the majority of cells after exposure to enzalutamide and abiraterone.

Original language	English
Article number	6083
Journal	Cancers
Volume	13
Issue number	23
DOIs	https://doi.org/10.3390/cancers13236083
Publication status	Published - 1 Dec 2021

Keywords

Drug screening
Microwell arrays
Prostate-specific antigen (PSA)
Protein secretion
Single cancer cells
UT-Gold-D

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13236083Licence: CC BY

cancers-13-06083Final published version, 4.09 MBLicence: CC BY

Cite this

@article{7f8dc31137824370b19f05964c8c07ad,

title = "Measurement of the drug sensitivity of single prostate cancer cells",

abstract = "The treatment of cancer faces a serious challenge as cancer cells within patients are heterogeneous and frequently resistant to therapeutic drugs. Here, we introduce a technology enabling the assessment of single cancer cells exposed to different drugs. PCa cells were individually sorted in self-seeding microwells, cultured for 24 h, and then exposed to several drugs to induce (R1881) or inhibit (Enzalutamide/Abiraterone) the secretion of a protein (PSA). Cell viability and PSA secretion of each individual prostate cell were monitored over a 3-day period. The PSA protein secreted by each cell was captured on a PVDF membrane through a pore in the bottom of each well. The basal PSA secretion was found to be 6.1 ± 4.5 and 3.7 ± 1.9 pg/cell/day for LNCaP and VCaP, respectively. After exposure to R1881, the PSA secretion increased by ~90% on average and was not altered for ~10% of the cells. PSA production decreased in the majority of cells after exposure to enzalutamide and abiraterone.",

keywords = "Drug screening, Microwell arrays, Prostate-specific antigen (PSA), Protein secretion, Single cancer cells, UT-Gold-D",

author = "Fikri Abali and Narges Baghi and Lisanne Mout and Broekmaat, {Joska J.} and Tibbe, {Arjan G.J.} and Terstappen, {Leon W.M.M.}",

note = "Funding Information: This research is funded by the NWO, The Netherlands Organization for Scientific Research (Utrecht, The Netherlands), under project number 15327. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. Financial transaction number: 342160541 ",

year = "2021",

month = dec,

day = "1",

doi = "10.3390/cancers13236083",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "MDPI",

number = "23",

}

TY - JOUR

T1 - Measurement of the drug sensitivity of single prostate cancer cells

AU - Abali, Fikri

AU - Baghi, Narges

AU - Mout, Lisanne

AU - Broekmaat, Joska J.

AU - Tibbe, Arjan G.J.

AU - Terstappen, Leon W.M.M.

N1 - Funding Information: This research is funded by the NWO, The Netherlands Organization for Scientific Research (Utrecht, The Netherlands), under project number 15327. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. Financial transaction number: 342160541

PY - 2021/12/1

Y1 - 2021/12/1

N2 - The treatment of cancer faces a serious challenge as cancer cells within patients are heterogeneous and frequently resistant to therapeutic drugs. Here, we introduce a technology enabling the assessment of single cancer cells exposed to different drugs. PCa cells were individually sorted in self-seeding microwells, cultured for 24 h, and then exposed to several drugs to induce (R1881) or inhibit (Enzalutamide/Abiraterone) the secretion of a protein (PSA). Cell viability and PSA secretion of each individual prostate cell were monitored over a 3-day period. The PSA protein secreted by each cell was captured on a PVDF membrane through a pore in the bottom of each well. The basal PSA secretion was found to be 6.1 ± 4.5 and 3.7 ± 1.9 pg/cell/day for LNCaP and VCaP, respectively. After exposure to R1881, the PSA secretion increased by ~90% on average and was not altered for ~10% of the cells. PSA production decreased in the majority of cells after exposure to enzalutamide and abiraterone.

AB - The treatment of cancer faces a serious challenge as cancer cells within patients are heterogeneous and frequently resistant to therapeutic drugs. Here, we introduce a technology enabling the assessment of single cancer cells exposed to different drugs. PCa cells were individually sorted in self-seeding microwells, cultured for 24 h, and then exposed to several drugs to induce (R1881) or inhibit (Enzalutamide/Abiraterone) the secretion of a protein (PSA). Cell viability and PSA secretion of each individual prostate cell were monitored over a 3-day period. The PSA protein secreted by each cell was captured on a PVDF membrane through a pore in the bottom of each well. The basal PSA secretion was found to be 6.1 ± 4.5 and 3.7 ± 1.9 pg/cell/day for LNCaP and VCaP, respectively. After exposure to R1881, the PSA secretion increased by ~90% on average and was not altered for ~10% of the cells. PSA production decreased in the majority of cells after exposure to enzalutamide and abiraterone.

KW - Drug screening

KW - Microwell arrays

KW - Prostate-specific antigen (PSA)

KW - Protein secretion

KW - Single cancer cells

KW - UT-Gold-D

UR - http://www.scopus.com/inward/record.url?scp=85120345029&partnerID=8YFLogxK

U2 - 10.3390/cancers13236083

DO - 10.3390/cancers13236083

M3 - Article

AN - SCOPUS:85120345029

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 23

M1 - 6083

ER -

Measurement of the drug sensitivity of single prostate cancer cells

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this